Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2013. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMRs), or connected persons, specifically regarding the GlaxoSmithKline UK and US Performance Share Plans.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share plan transactions. The only financial data points disclosed are the share prices used for notional re-investment on April 17, 2013:
- Ordinary Share Price: 1565.50 pence
- American Depositary Share (ADS) Price: $48.52
Material Changes
The filing details increases in notional interests in Ordinary Shares and ADSs following the re-investment of dividends paid on April 11, 2013. Specific changes include:
- Dr M M Slaoui: Increase of 24.631 ADSs (Connected Person: Dr K Slaoui).
- Mr P C Thomson: Increase of 58.640 Ordinary Shares (Connected Person: Mrs K Thomson).
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It notes that notional dividends accrued will be paid out in proportion to the percentage of the participant's Performance Share Plan holdings that vest following the end of the relevant three-year measurement period. The transaction was notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c).
Investor Verification Checklist
- Verify the vesting schedule and measurement period for the UK and US Performance Share Plans to understand future payout timing.
- Confirm the total number of shares held by Dr M M Slaoui and Mr P C Thomson post-transaction to assess total exposure.
- Review the dividend payment details from April 11, 2013, to validate the basis for the notional re-investment.